Join

Compare · OM vs TMDX

OM vs TMDX

Side-by-side comparison of Outset Medical Inc. (OM) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both OM and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • TMDX is the larger of the two at $2.41B, about 28.2x OM ($85.3M).
  • OM has been more active in the news (14 items in the past 4 weeks vs 12 for TMDX).
  • TMDX has more recent analyst coverage (18 ratings vs 13 for OM).
MetricOMTMDX
Company
Outset Medical Inc.
TransMedics Group Inc.
Price
-
-
Market cap
$85.3M
$2.41B
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2020
2019
News (4w)
14
12
Recent ratings
13
18
OM

Outset Medical Inc.

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

TMDX

TransMedics Group Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Latest OM

Latest TMDX